Teva's 2009 Sales Boosted By Copaxone

Israeli generic drugmaker Teva has announced its full-year unaudited financial results, with a profitable Q409 pushing sales above 2008 levels. BMI believes much of the firm's sales growth can be attributed to more aggressive US directed sales, the success of its patented

To read the full article, please choose one of the following options: